October 28, 2026

FDA scientists opposed HHS plan to ease access to unproven peptides

FDA staff warned the peptides had not been shown safe or effective and cited risks including allergic reactions, kidney damage and tumor growth.
HHS shifted from a proposed regulation declaring the substances safe for compounding to a policy limiting enforcement.
The draft includes safeguards such as requiring FDA-regulated ingredient sources and collecting side-effect information.

Read the news this way every day.

Concur organizes political reporting into clear stories and shows the sources behind each one.

Free. No ads.